AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says
If approved, uniQure’s AMT-130 would be the first disease-modifying treatment for the inherited neurodegenerative disorder.
Cytiva Navigating cell therapy WP 4
Cellares and Sonoma partner to automate cell therapy manufacturing
Apertura and NIH institutes to test gene therapy for NPC1
Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline
FDA widens Vertex’s Casgevy use for paediatric patients
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy
